INTRODUCTION
ADAM17 (a disintegrin and metalloproteinase 17) also known as TACE [TNF (tumour necrosis factor) α-converting enzyme] has been identified as a transmembrane protease responsible for the cleavage of the type II transmembrane protein TNFα [1, 2] . The extracellular portion of ADAM17 consists of a prodomain, a catalytic domain, a cysteine-rich domain comprising a disintegrin-like domain and a membrane-proximal cysteine-rich extension followed by a transmembrane domain and intracellular region. The membrane-proximal cysteine-rich extension has been implicated in substrate recognition [3] and dimerization [4] of the ADAM17 protease.
Besides the processing of TNFα, ADAM17 is also responsible for the cleavage of IL-6R (interleukin 6 receptor) [5] and several ligands of EGF-R (epidermal growth factor receptor) [6] . ADAM17 − / − mice are not viable and show defects in the mammary epithelium, vascular system, lung, eye, hair, heart and skin and the phenotype is reminiscent of mice lacking EGF-R ligands such as TGFα (transforming growth factor α) [7] . Conditional knockout of ADAM17 generates mice with ADAM17-deficient leukocytes, monocytes and granulocytes that are protected from LPS (lipopolysaccharide)-induced septic shock [8] and that showed protection from Escherichia coliinduced peritonitis [9] . Mice hypomorphic for ADAM17 in all tissues exhibited strongly increased susceptibility to inflammatory bowel disease owing to impaired regeneration of the intestinal epithilium, a process dependent on EGF-R activation [10, 11] .
The activity of ADAM17 is mainly controlled at the posttranscriptional level [6] with ADAM17 localized primarily in the endoplasmic reticulum. Activation of cells via ERK (extracellularsignal-regulated kinase) activation and phosphorylation of Thr 735 was shown to lead to exposure of activated ADAM17 at the cell surface [12] . Recently, the involvement of the proteolytically inactive member of the rhomboid family iRhom2 (inactive rhomboid protein 2) in the control of ADAM17 trafficking to the cell surface was demonstrated [13, 14] .
The growth of many tumour cells depends on EGF-R trans-activation [15, 16] . ADAM17 activity is necessary for transactivation of the EGF-R via cleavage of EGF-R ligands such as TGFα, amphiregulin and HB-EGF (heparin-binding epidermal growth factor-like growth factor) [17] . Interestingly, the cleavage of Notch1 by ADAM17 also contributed to the activation of the EGF-R pathway in non-small-cell lung cancer [18] . Increased cell surface expression and up-regulation of ADAM17 has been observed in many tumour cells, such as breast, ovarian, prostate, colon and pancreatic cancer cells [15, 16, [19] [20] [21] [22] [23] . Therefore, ADAM17 has been implicated as a therapeutic target for the treatment of various cancers [6, 15, 16, [19] [20] [21] .
Effective targeting of various cancer cells has recently been demonstrated with the use of BiTEs (bispecific T-cell engager antibodies), which on the one hand bind to tumour-cell-specific cell surface proteins and on the other hand attract cytotoxic T-cells by binding and activating CD3 [24, 25] . This approach has resulted in highly effective killing of KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue)-and BRAF (v-raf murine sarcoma viral oncogene homologue B1)-mutated colorectal cancer cells by human T-cells in mice. Also, in patients with nonHodgkin's lymphomas and B-cell precursor acute lymphoblastic leukaemia and in patients with lung and gastrointestinal cancer, very efficient killing of tumour cells has been demonstrated [24, 25] .
In the present study we have generated a new mAb (monoclonal antibody) called A300E that recognizes the membrane-proximal cysteine-rich extension of human ADAM17. The DNA sequences coding for the variable heavy and light chain were used to generate a recombinant scFv (single-chain variable fragment) antibody with the same specificity. Using this scFv we constructed a bispecific antibody recognizing ADAM17 on tumour cells and CD3 on T-cells (A300E-BiTE). Finally, we demonstrated that, in the presence of human T-cells, A300E-BiTE led to the specific killing of human prostate cancer cells.
MATERIALS AND METHODS

Selection, expression and purification of A300E mAb
A new mAb (A300E) recognizing the membrane-proximal cysteine-rich extension of ADAM17 was generated using the methods described by Trad et al. [26] . Hybridoma cells of the clone A300E producing mAbs against ADAM17 were cultivated in serum-free medium (Hybridoma Express Plus, PAA Laboratories) and the antibody was purified via HiTrap Protein G High Performance, as described previously [26] . The purity of the antibody preparation was verified by SDS/PAGE (10% gel). The subclass of the mAbs was determined by using a mouse isotyping kit (Pierce) according to the manufacturer's instructions.
Amplification of V H and V L chains from A300E mAb
Total RNA was prepared from hybridoma cells of the clone A300E expressing the anti-ADAM17 mAb using the NucleoSpin RNAII kit (Macherey-Nagel) according to the manufacturer's instructions. The cDNA was synthesized from RNA samples using the Revert Aid Reverse Transcriptase kit (Fermentas) according to the manufacturer's protocol. Universal primers for variable heavy or light chains were designed based on previous publications (Supplementary Table S1 at http://www.BiochemJ. org/bj/445/bj4450135add.htm) [27, 28] . Using these primers together with cDNA as a template, PCR was carried out by Dream Taq polymerase (Fermentas). PCR products were sequenced by GATC Biotech.
Expression and purification of A300E-scFv
The cDNA coding for the ADAM17-specific scFv (A300E-scFv) was synthesized by GenScript and then subcloned into the bacterial expression vector pET23a (Novagen) which contained a pelB-based leader sequence upstream and sequences coding for the c-Myc and His tags downstream of the scFv cDNA insert. The pET23a-A300E-scFv was transformed into BL21 DE3 pLysS cells. The transformed cells were grown at 37
• C in LB (lysogeny broth) medium supplemented with ampicillin (100 μg/ml), and protein expression was induced by 1 mM IPTG (isopropyl β-D-thiogalactopyranoside) at D 600 = 0.6-0.8 at 28
• C. After overnight culture, the supernatant was collected and centrifuged to remove the bacterial cells. scFv proteins secreted into the culture supernatant were purified using a Ni-HiTrap column (GE Healthcare) and eluted by increasing imidazole concentrations. The fractions which contained the A300E-scFv were further purified via a Superdex75 16/60 column (GE Healthcare) equilibrated in PBS. The purified A300E-scFv protein was collected and concentrated to 100 μg/ml.
Expression and purification of A300E-BiTE
The cDNA coding for the ADAM17-specific BiTE (A300E-BiTE) was synthesized by GenScript and then subcloned into the mammalian expression vector pcDNA 3.1 (Invitrogen). CHO (Chinese hamster ovary) cells were transfected with the pcDNA3.1-A300E-BiTE by liposome transfection (Turbofect, Fermentas) according to the manufacturer's protocol. Stably transfected cells were selected with G418 (final concentration, 500 μg/ml) and BiTE expression was verified by Western blotting using the anti-c-Myc mAb (9E10, Santa Cruz Biotechnology) as the primary antibody. For production of A300E-BiTE, transfected cells were grown for 7 days in 175 cm 2 tissue culture flasks (Sarstedt) with DMEM (Dulbecco's modified Eagle's medium)/nutrient mixture Ham's F-12 (1:1) including 5 % FBS (fetal bovine serum). The dead cells were removed by centrifugation and the supernatant was stored at − 20
• C. BiTE proteins secreted into the supernatant were purified by Ni-HiTrap column (GE Healthcare) and eluted by increasing imidazole concentrations. Fractions containing A300E-BiTE were further purified via a Superdex 200 16/60 column (GE Healthcare) equilibrated in PBS. The purified A300E-BiTE protein was collected and concentrated to 100 μg/ml.
Western blotting
A 20 μl sample volume was loaded on to SDS/PAGE (10 % gel). After separation, the proteins were transferred on to a PVDF membrane (GE Healthcare). The membrane was blocked with 5 % non-fat dried skimmed milk powder in 10 mM Tris/HCl (pH 7.4) and 150 mM NaCl for 2 h. Depending on the protein, the membrane was probed with the formerly described A300 mAb, which recognized the disintegrin-like domain of human ADAM17 [26] , A300E mAb (produced in the present study), anti-c-Myc mAb (9E10, Santa Cruz Biotechnology) or anti-β-actin mAb (Santa Cruz Biotechnology). Each primary antibody was diluted 1:1000 with 5 % non-fat dried skimmed milk powder in TBS-T [Tris-buffered saline with Tween 20; 10 mM Tris/HCl (pH 7.4), 150 mM NaCl and 0.05 % Tween 20]. After incubation at 4
• C overnight, the membranes were washed with TBS-T and incubated with anti-mouse IgG coupled to horseradish peroxidase (Pierce) for 2 h at room temperature (22 • C). After washing with TBS-T, the protein bands were visualized using the ECL (enhanced chemiluminescence) detection system (GE Healthcare) according to the manufacturer's instructions.
Cell lines and culture
The prostate cancer cell line PC3 was obtained from the A.T.C.C. The MDA-MB-231 breast cancer cell line and the COLO357 and Panc89 pancreatic cancer cell lines were a gift from Dr Holger Kalthoff (Universitätsklinikum Schleswig-Holstein, Kiel, Germany). The Jurkat T-cell line was a gift from Dr Dieter Adam (Universitätsklinikum Schleswig-Holstein, Kiel, Germany). HCT116 colorectal cancer cells and SW620 colon cancer cells were obtained from Dr Richard Moriggl (Ludwig Boltzmann Institute for Cancer Research, Vienna, Austria). CHO cells stably expressing the cysteine-rich domain of human ADAM17 comprising a disintegrin-like domain and a membraneproximal cysteine-rich extension followed by the transmembrane region of human ADAM17 (CHO-ADAM17_DE) were generated by stable transfection and selection with G418 (final concentration of 500 μg/ml). Transfection of cells was verified by Western blotting using A300 mAb [26] . Cancer cell lines were cultivated in RPMI-1640 medium supplemented with 10 % FBS (PAA Laboratories) at 37
• C in a 5% CO 2 humidified incubator. CHO cells were cultivated in Ham's F-12 medium containing 10 % FBS. HEK (human embryonic kidney)-293 cells were cultivated in DMEM high-glucose containing 10 % FBS.
Cytotoxicity assay
Redirected cellular cytotoxicity was assayed by flow cytometry using human PBMCs (peripheral blood mononuclear cells) or isolated T-cells as the effector cells and various ADAM17-positive human carcinoma cell lines or transfected CHO cells as the targets. PBMCs were isolated from healthy donors by Ficoll density gradient centrifugation using standard procedures. Approval was obtained from the University Hospital SchleswigHolstein institutional review board. Informed consent was obtained in accordance with the Declaration of Helsinki. Briefly, after centrifugation, cells were incubated in 10 ml of erythrocyte lysis buffer (Sigma-Aldrich) at room temperature for 10 min, washed with PBS, suspended in RPMI-1640 medium and the cell number was adjusted to 6×10 6 cells/ml. Alternatively, T-cells were isolated from PBMCs using the Pan T-cell Isolation Kit II (Miltenyi Biotec) according to the manufacturer's instructions. For activation of T-cells, 2×10 6 Tcells were cultured in 24-well plates in which 1 μg of anti-CD3 antibody and 1 μg of anti-CD28 antibody (eBioscience) were immobilized. The cells were incubated for 3 days at 37
• C in a 5% CO 2 humidified incubator. Target cells were stained with PKH26 fluorescent membrane dye according to the manufacturer's instructions (Sigma-Aldrich). Cells were adjusted to 6×10 5 cells/ml in RPMI-1640 medium. Equal volumes of target and effector cell suspension were then mixed and 50 μl of this suspension was transferred to each well of a 96-well round bottom plate. A 50 μl aliquot of an A300E-BiTE serial dilution or of RPMI-1640 medium as a negative control were added. Unless otherwise indicated, the plates were incubated for 24 h and 48 h at 37
• C in a 5% CO 2 humidified incubator. Cells were washed once in FACS buffer (PBS, 2 % FBS and 0.02 % NaN 3 ) and incubated at 4
• C in 200 μl vol. for 30 min. PI (propidium iodide) was added to a final concentration of 1 μg/ml and the samples were analysed by flow cytometry on a FACScan flow cytometer (BD Biosciences). Target cell lysis was determined as the percentage of cells stained by PI. All of the incubations were performed in duplicate.
Flow cytometry
The cells were washed twice in PBS containing 0.05 % NaN 3 and suspended in staining buffer (PBS, 5 % FBS and 0.05 % NaN 3 ). Cells (10 6 ) were stained for 1 h at 4
• C with 2 μg/ml of A300E mAb or 2 μg/ml of A300-BiTE and 1 μg/ml of anti-cMyc mAb. Cells were washed twice in PBS containing 0.05 % NaN 3 followed by addition of 100 μl of APC (allophycocyanin)-labelled donkey anti-mouse IgG (eBioscience) diluted 1:200 in staining buffer. The cells were then incubated for 1 h at 4
• C and washed twice with PBS and 0.05 % NaN 3 . The samples were analysed by flow cytometry on a FACScan flow cytometer. The cell populations of interest were gated and analysed using BD FACSDiva software.
ELISA
Microtitre plates (Nunc) were coated with 50 μl per well of purified bacterially expressed cysteine-rich domain of human ADAM17 comprising a disintegrin-like domain and a membraneproximal cysteine-rich extension (ADAM17_DE), a disintegrinlike domain (ADAM17_D), or membrane-proximal cysteine-rich extension (ADAM17_E) of ADAM17 [26] at 10 μg/ml in coating buffer (0.5 M carbonate/bicarbonate buffer, pH 9.6) per well and incubated for 2 h at room temperature. The plates were washed with PBS-T (PBS and 0.05 % Tween) and blocked with 3 % BSA in PBS for 2 h at room temperature. After washing, 50 μl of A300 mAb [26] , A300E mAb and A300E-scFv or BiTE and anti-c-Myc mAb were added as primary antibodies and incubated for 1 h at room temperature. As a negative control, the assay was performed without anti-ADAM17 mAbs, scFv and BiTE molecules. The plates were washed with PBS-T and the mAbs were detected using anti-mouse IgG coupled to horseradish peroxidase (Pierce) diluted 1:5000 with 1 % BSA in PBS. After washing, each well was incubated with 50 μl of BM Blue POD (peroxidase) substrate (Roche) in the dark at room temperature for 10 min. The reaction was stopped by adding 50 μl of 1.8 M H 2 SO 4 . The D of each well was measured at 450/540 nm on a plate reader (TECAN).
Immunoprecipitation
HEK-293 cells and CHO-ADAM17_DE were cultured in 10-cm-diameter culture dishes (Sarstedt) and lysed in 250 μl of lysis buffer containing 50 mM Tris/HCl (pH 7.5), 150 mM NaCl, 0.5 % Nonidet P40 and 'complete' protease inhibitor mixture without EDTA (Roche), incubated for 2 h at 4
• C by gently rotating and centrifuged for 30 min at 20 800 g at 4
• C. After centrifugation, 200 μl of lysate was collected. In parallel, 5 μg of purified A300E mAb or 5 μg of A300E-BiTE and 5 μg of anti-c-Myc mAb were added into 50 μl of Protein G-agarose (Thermo Scientific) and incubated overnight at 4
• C under gentle rotation. After incubation, Protein G-agarose was washed with PBS, added to 200 μl of lysate and incubated for 6 h at 4
• C under gentle rotation. Afterwards, Protein G-agarose was washed five times with washing buffer [10 mM Tris/HCl (pH 7.6), 150 mM NaCl, 0.2 % Nonidet P40 and 2 mM EDTA], mixed with 50 μl of 2-fold-concentrated SDS sample buffer including 5 % 2-mercaptoethanol and boiled at 95
• C for 5 min. After centrifugation, the supernatants were collected as samples for Western blotting.
CD spectroscopy
CD measurements were carried out with a Jasco-J-720-CD spectropolarimeter (Japan Spectroscopic Company). Proteins were dissolved to a concentration of 200 μg/ml in PBS, pH 7.4. The spectral bandwidth was 2 nm. The thermal stability was measured at 222 nm with increasing temperatures. The spectropolarimeter was calibrated according to Chen and Yang [29] .
RESULTS
Generation and characterization of novel mAbs against human ADAM17
Recently, we reported on the generation of several mAbs directed against the disintegrin-like domain of the human ADAM17 protein [26] . In the present paper we generated a different anti-ADAM17 mAb (A300E) using a recombinant bacterially expressed fragment of the cysteine-rich domain (ADAM17_DE) of human ADAM17 comprising a disintegrin-like domain [26] . Right-hand panel, ADAM17_DE consisting of the cysteine-rich domain (DE) followed by the transmembrane region (TM) of human ADAM17 (amino acids 475-694). Pro, pro-domain; CD, catalytic domain; TM, transmembrane region; IR, intracellular region. (B) Determination of antigen specificity of A300 [26] and A300E mAbs by ELISA. Microtitre plates (96-well) were coated with the recombinant cysteine-rich domain comprising a disintegrin-like and a membrane-proximal cysteine-rich extension (DE), disintegrin-like domain (D) or the membrane-proximal cysteine-rich extension (E) of human ADAM17 (10 μg/ml each) and blocked with 3 % BSA in PBS. Each mAb (1 μg/ml) was added and incubated for 1 h. The detection of primary antibody has been performed by addition of horseradish peroxidase-labelled goat anti-mouse IgG as a secondary antibody. Negative control (NC) was performed without primary antibody. Results are means + − S.D. (C) Determination of antigen specificity of A300 [26] and A300E mAbs by Western blotting. Recombinant DE, D and E domains (500 ng/ml) were applied to SDS/PAGE. Both A300 and A300E mAbs were used as primary antibody. Note that a band of approximately 50 kDa is also recognized by A300 mAb, which could represent an SDS-resistant dimer of the disintegrin-like domain of ADAM17. (D) Immunoprecipitation of ADAM17 and ADAM17_DE form by A300 and A300E mAbs. Endogenous human ADAM17 and truncated form ADAM17 (ADAM17_DE) were immunoprecipitated with A300 or A300E mAbs (5 μg each) from HEK-293 (upper panel) and CHO-ADAM17_DE (lower panel) lysates respectively. Negative control ( − mAb) was performed without capture antibody. ADAM17 was detected by A300 mAb using Western blotting. CHO-ADAM17_DE, CHO cells stably expressing the cysteine-rich domain comprising a disintegrin-like domain and a membrane-proximal cysteine-rich extension followed by the transmembrane region of human ADAM17. (E) Western blot analysis of ADAM17 knockdown in NCI-H292 cells using ADAM17 shRNA (hA17sh) compared with cells infected with empty (Con) vector. ADAM17 was detected by using A300 mAb as the primary antibody. β-Actin was used as the loading control. (F) Specific recognition of human ADAM17 on NCI-H292 control cells and ADAM17 shRNA (shA17)-transfected cells by flow cytometry using A300E mAb. The two NCI-H292 cell lines were treated with A300E mAb (grey peaks) and isotype-matched control antibody (white peaks) and then with APC-labelled donkey anti-mouse IgG. For the Western blots, the molecular mass is given in kDa on the left-hand side.
(ADAM17_D) and a membrane-proximal cysteine-rich extension (ADAM17_E) as antigen for the immunization of mice (see Materials and methods section and Figure 1A ). As shown in Figure 1(B) , the ADAM17 mAb A300 [26] recognized the ADAM17 disintegrin-like domain (ADAM17_D) as demonstrated by ELISA measurement using purified recombinant fragments of human ADAM17. In contrast, the new mAb A300E specifically bound to the membrane-proximal cysteine-rich extension (ADAM17_E) of ADAM17. These results were confirmed by Western blot analysis. Again, the anti-ADAM17 mAb A300 [26] recognized the disintegrin-like domain (ADAM17_D) of ADAM17, whereas the A300E mAb detected the membrane-proximal cysteine-rich extension (ADAM17_E) of ADAM17 ( Figure 1C) , indicating that the denatured ADAM17 was recognized by both mAbs. To ask whether the anti-ADAM17 mAbs recognized the cellular ADAM17 protein, immunoprecipitation experiments were performed. As shown in Figure 1(D) , the mAb A300E, but not the A300 mAb [26] , precipitated the pro-and mature form of ADAM17 from lysates of HEK-293 cells as visualized by Western blotting. Interestingly, when CHO cells were stably transfected with a cDNA encoding for a deletion mutant of ADAM17 containing only the Table S1 at http://www.BiochemJ.org/bj/445/bj4450135add.htm). After analysis of DNA sequences from V H and V L fragments the construct of A300E-scFv and BiTE were introduced into pET23a and pcDNA3.1 vectors respectively. Linker indicates flexible linker (Gly 4 Ser). The c-Myc and His 6 tags are fused for detection and purification respectively. (B) Purity and integrity of the recombinant A300E-BiTE. After collection of the supernatant from CHO cells stably expressing A300E-BiTE, the recombinant BiTE was purified by affinity chromatography with a Ni-NTA (Ni 2 + -nitrilotriacetate) column and gel-filtration chromatography, and then analysed using SDS/PAGE under reducing conditions. Gels were either stained with Coomassie Brilliant Blue (CBB) or blotted on to a PVDF membrane. Recombinant BiTE was detected with anti-c-Myc mAb (WB). (C) The thermal stability assay of A300E-BiTE was examined by CD by following spectral changes at 222 nm with increasing temperature.
disintegrin-like domain and membrane-proximal cysteine-rich extension of human ADAM17 followed by the transmembrane region (ADAM17_DE) [4] , it turned out that both mAbs, A300 [26] and A300E, recognized the truncated ADAM17 protein (designated ADAM17_DE in Figure 1A ) ( Figure 1D , lower panel). As an additional test for the specificity of the A300E mAb, we used the human non-small lung cancer cell line NCI-H292, which express ADAM17 and the same cells stably transfected with an ADAM17 shRNA (short hairpin RNA) [18] . As shown in Figure 1 (E), we detected endogenous ADAM17 in NCI-H292 cells and in NCI-H292-hA17sh cells, in which ADAM17 had been down-regulated by the shRNA, by Western blotting using A300 mAb [26] . ADAM17 expression was drastically reduced in NCI-H292-hA17sh cells as compared with NCI-H292 cells, which were infected with empty vector. These results were further corroborated by FACS analysis of the NCI-H292 cells. As shown in Figure 1(F) , the A300E mAb detected ADAM17 on the cell surface of NCI-H292 cells (left-hand panel). Significantly less ADAM17 was detected on the surface of shRNA-transfected NCI-H292 cells (right-hand panel). We conclude from these experiments that the ADAM17 mAb A300E specifically detects the membrane-proximal cysteine-rich extension (ADAM17_E) of human ADAM17 and that it recognizes the denatured as well as the native protein and can therefore be used for ELISA, Western blotting, immunoprecipitation and FACS analysis.
ADAM17 is overexpressed on the surface of a variety of cancer cells
It has been reported that most tumour cells show strongly increased cell surface expression and activation of ADAM17 [15] . We therefore analysed several human tumour cell lines for cell surface expression of ADAM17. After having shown that the ADAM17-specific mAb A300E recognized truncated ADAM17_DE on the cell surface of stably transfected CHO cells (Supplementary Figure S1A) , we investigated the pancreatic cancer cell lines COLO357 and Panc89, the breast cancer cell line MDA-MB-231, and the prostate cancer cell line PC3. As shown in Supplementary Figure S1(B) , all of the cell lines express ADAM17 on the cell surface. We next extended our analysis to the human Jurkat T-cells as well as to primary human PBMCs. As shown in Supplementary Figure S1 (C), we detected considerably less ADAM17 protein on the cell surface of Jurkat T-cells and human PBMCs as compared with the tumour cell lines. We conclude from these results that the ADAM17-specific mAb A300E can be used to detect ADAM17 on human cell lines and that the human tumour cell lines COLO357, Panc89, MDA-MB-231 and PC3 express large amounts of ADAM17 on the cell surface and that human Jurkat T-cells and PBMCs express no appreciable amounts of ADAM17 on the cell surface.
Generation of the recombinant BiTE against human ADAM17 and CD3
After having established by ELISA that the mAb A300E belongs to the subclass IgG1 (results not shown) we amplified the cDNAsequences coding for the variable regions of the heavy chain (V H ) and light chain (V L ) of the mAb A300E. We used ten and seven primer sets to amplify V H and V L cDNAs respectively as indicated in Figure 2 (A) and Supplementary Table S1 (at http://www. BiochemJ.org/bj/445/bj4450135add.htm). These sequences were used to generate scFv corresponding to the mAb A300E (Figure 2A ). The cDNA coding for the A300E-scFv was transfected into BL21 (DE3) pLysS bacteria. After induction with IPTG, the scFv protein was purified by affinity and size-exclusion chromatography as demonstrated using SDS/PAGE followed by Western blotting. As shown in Supplementary Figure S2 (A) (at http://www.BiochemJ.org/bj/445/bj4450135add.htm), upon SDS/PAGE the A300E-scFv migrated according to the calculated mass of 31 kDa. No signs of degradation were detected. The yield of the purified scFv was in the range of 1 mg/l of supernatant. In addition, the purified scFv bound to endogenous ADAM17 on the surface of HEK-293 cells and to the truncated version of ADAM17, ADAM17_DE, on the surface of transfected HEK-293 cells (Supplementary Figures S2B and S2C) . Furthermore, we used the CD3 targeting sequence of the bispecific antibody blinatumomab, which has been shown to engage cytotoxic Tcells [24] , to construct a bispecific ADAM17-and CD3-binding antibody (A300E-BiTE) (Figure 2A ). The nucleotide sequence and amino acid sequence of the bispecific A300E-BiTE is shown in Supplementary Figure S3 (at http://www.BiochemJ. org/bj/445/bj4450135add.htm). The cDNA encoding A300E-BiTE was stably transfected into CHO cells. The A300E-BiTE protein was purified to homogeneity via affinity and sizeexclusion chromatography as demonstrated using SDS/PAGE followed by Western blotting. Upon SDS/PAGE the A300E-BiTE protein migrated according to the calculated mass of 57 kDa. No signs of degradation were detected. The yield of the purified BiTE ranged from 50-100 μg/l of cell culture supernatant ( Figure 2B ). Thermal stability of A300E-BiTE was assessed using CD spectroscopy by following changes at 222 nm at different temperatures. As shown in Figure 2(C) , the A300E-BiTE molecule was stable up to a temperature of 55
• C. At temperatures higher than 70
• C the protein precipitated.
Characterization of the recombinant BiTE against human ADAM17 and CD3
We next asked whether the specificity of the A300E-BiTE was unaltered by the reformatting procedure. As shown in Figure 3(A) , the parental A300E mAb, the scFv antibody and the bispecific A300E-BiTE recognized the membrane proximal cysteine-rich extension (ADAM17_E) of ADAM17 as demonstrated by ELISA measurements. Furthermore, as shown in Figure 3 Next we demonstrated that A300E-BiTE also recognized the endogenous ADAM17 on NCI-H292 cells ( Figure 3C , left-hand panel), whereas very little ADAM17 protein was detected on the surface of NCI-H292-hA17sh cells ( Figure 3C , right-hand panel). We conclude from these data that reformatting of the A300E mAb to a scFv and to a bispecific A300E-BiTE conserved its specificity and that A300E-BiTE recognized the endogenous ADAM17 protein on the surface of cells.
A300E-BiTE recognized both endogenous ADAM17 and CD3 on the surface of cells
We investigated whether A300E-BiTE also recognized ADAM17 on the surface of tumour cells. First, we verified that the truncated version of ADAM17_DE on the surface of transfected CHO cells was detected ( Figure 4A ). Next, we demonstrated that A300E-BiTE also bound to the endogenous ADAM17 protein on the surface of the human tumour cell lines COLO357, Panc89, MDA-MB-231 and PC3. Please note that recognition of ADAM17 by A300E-BiTE was somewhat less efficient as compared with recognition by the parental A300E mAb (compare Supplementary Figure S1B and Figure 4B ). Finally, we showed that the A300E-BiTE also bound to CD3 on the surface of Jurkat T-cells ( Figure 4C , left panel) and of primary human PBMCs ( Figure 4C , right-hand panel). We conclude from these data that A300E-BiTE recognized both endogenous ADAM17 and CD3 on the surface of cells with a similar specificity as the parental A300E mAb.
A300E-BiTE mediates lysis of PBMCs with T-cells as effector cells
Since bispecific antibodies such as A300E-BiTE have been used to induce killing of tumour cells in the presence of human T-cells we asked whether ADAM17-specific cellular lysis could be induced by the A300E-BiTE protein. First, we incubated untransfected CHO cells and CHO cells stably transfected with the truncated ADAM17_DE form together with freshly isolated human PBMCs at an E:T (effector to target cell ratio) of 10:1 in the presence of increasing concentrations of purified A300E-BiTE protein.
As can be seen in Figure 5 (A), increasing amounts of A300E-BiTE led to the lysis of the ADAM17_DE-transfected CHO cells, but not of the parental CHO cells after 24 h (redirected lysis of CHO-ADAM17_DE approaching about 15 %) and to a larger extent after 48 h (redirected lysis of CHO-ADAM17_DE approaching about 35 %), clearly demonstrating the specificity of A300E-BiTE-mediated cellular killing. Similarly, when we incubated prostate cancer cells (PC3) with human freshly isolated PBMCs and A300E-BiTE, we also observed A300E-BiTE-mediated killing of the tumour cells, which again was more pronounced after 48 h (redirected lysis approaching about 40 %) than after 24 h (redirected lysis approaching about 16 %) ( Figure 5B ). A300E-BiTE-mediated killing of the CHO cells transfected with the truncated ADAM17_DE form and the PC3 prostate cancer cells is shown in Figure 5 (C). Similar results of A300E-BiTE-mediated cellular killing was observed when freshly isolated human T-cells were used as effector cells. As shown in Figure 5 (D), CHO cells transfected with the truncated ADAM17_DE form and PC3 prostate cancer cells were killed upon addition of A300E-BiTE (redirected lysis approaching about 24 % and 27 % respectively), whereas untransfected CHO cells remained unaffected. Killing of the tumour cell lines such as MDA-MB-231 breast cancer cells, HCT116 colorectal cancer cells and SW620 colon cancer cells was also strongly enhanced by the addition of A300E-BiTE in the presence of a human T-cell line (results not shown). Cellular lysis of CHO cells transfected with the truncated ADAM17_DE form and PC3 prostate cancer cells was more pronounced when the human T-cells were activated by treatment with anti-CD3 and anti-CD28 antibodies ( Figure 5D , lower panel). Compared with Figure 5 (B) using PBMCs as effector cells, background lysis was lower after a 48 h incubation. No redirected cellular lysis was seen in untransfected CHO cells. We conclude from these results that the bispecific A300E-BiTE antibody led to cellular lysis of prostate cancer cells via recognition of ADAM17 on tumour cells and CD3 on T-cells.
and then with APC-labelled donkey anti-mouse IgG. Negative controls were stained with A300E-scFv and anti-c-Myc mAb (white peaks). 
DISCUSSION
In the present study we generated a novel mAb directed against the membrane-proximal cysteine-rich extension of the shedding protease ADAM17, which has been implicated in the shedding of several membrane proteins, including TNFα, L-selectin, IL-6R and several ligands of the EGF-R [6] . The preferential cell surface expression and activation of the ADAM17 protease in tumour cells has been used as an argument that ADAM17 might be a target for immunotherapy of human cancer [15, 16] . We have determined the cDNA sequence of the new ADAM17 antibody A300E and have used it to construct and generate a single-chain antibody and a bispecific anti-ADAM17 A300E-BiTE antibody with a CD3-binding component.
Previously, we have seen an impressive revival of the bispecific antibody technology, which was invented more than 15 years ago [30, 31] . Examples include the generation of a bispecific antibody with dual specificity for CD19 on B-cells and CD3 on T-cells. This antibody was shown to lead to partial and complete tumour regression in patients with non-Hodgkin's lymphoma and the same bispecific antibody is in clinical trials for the treatment of acute lymphoblastic leukaemia [24] . An additional BiTE antibody in clinical development is bispecific for CD3 and EpCAM (epithelial cell adhesion molecule) [32, 33] . It is currently being tested in a clinical trial with lung and gastrointestinal cancer patients. Other T-cell-engaging bispecific antibodies with specificities for other cell surface proteins such as the EGF-R, which is overexpressed in breast cancer, showed equally impressive results in preclinical studies with xenograft models [25] . In addition, a BiTE antibody recognizing CEA (carcinoembryonic antigen) and CD3 has been established and was shown to prevent subcutaneous tumour growth and formation of lung metastases in preclinical models [34, 35] . Only subpicomolar concentrations of the bispecific antibodies were required to redirect human T-cells to the tumour cells, making this technology extremely attractive for the use in human cancer therapy [24, 25] .
ADAM17 had been initially purified and molecularly cloned as the enzyme responsible for the cleavage of the membrane-bound inflammatory cytokine TNFα [1, 2] . It became clear, however, that ADAM17 was also responsible for the shedding of sIL-6R (soluble IL-6R), L-selectin and several ligands of EGF-R [6, 7, 36] . Meanwhile we know that at least 74 different membrane proteins are subject to cleavage by ADAM17 [6] . Although in the beginning it was thought that ADAM17 might be a promising target for the treatment of autoimmune diseases such as Rheumatoid arthritis [37] , it later turned out that ADAM17 also governs beneficial effects such as the regeneration of intestinal epithelial cells, which is important in inflammatory bowel disease [11, 38] . This led to the notion that ADAM17 orchestrates pro-and anti-inflammatory reactions and that a global blockade of ADAM17 activity might not be an option for the long-term treatment of patients with autoimmune diseases [6] .
It has been noted, however, that ADAM17 is involved in the activation of the EGF-R pathway via a process called transactivation [39] and that targeting of ADAM17 with smallmolecular-mass inhibitors or with siRNAs (small interfering RNAs) led to a significant reduction in tumour cell growth [18, 22, 23, 40] . In this respect it is important that ADAM17 cleaves ligands of the EGF-R, such as TGFα, amphiregulin and HB-EGF [17] , as cleavage of such ligands is a prerequisite for systemic EGF-R activity [38] . Recently it has also been recognized that cleavage of Notch1 by ADAM17 contributes to a positive-feedback loop leading to enhanced expression of EGF-R in non-small-cell lung cancer cells [18] . In view of these data it was not surprising that the ADAM17 protein is often highly expressed and activated on the surface of tumour cells and has been hypothesized to constitute a target for therapeutic approaches such as the immunotherapy of cancer [15, 16, 41] .
With regards to these previous studies, we have generated the first recombinant ADAM17-recognizing and T-cell-activating bispecific recombinant antibody, A300E-BiTE, and have shown that it redirects cellular lysis of ADAM17-transfected cells and human prostate cancer cells in the presence of human primary PBMCs and freshly isolated T-cells. It will be interesting in future studies whether ADAM17-directed T-cell-engaging bispecific antibodies will show killing of human tumour cells in xenograft models in the presence of human T-cells as used in the recent study by Lutterbuese et al. [25] . Such approaches might help to overcome problems with tumour-cell resistance seen in many therapeutic approaches targeting the growth promoting signalling activities of human cancers [42] . (A) After collection of the supernatant from BL21 (DE3) pLysS expressing A300E-scFv, the recombinant scFv was purified via a Ni-NTA (Ni 2 + -nitrilotriacetate) column and subsequent gel-filtration chromatography and was analysed using SDS/PAGE under reducing conditions. The gels were either stained with Coomassie Brilliant Blue (CBB) or blotted on to a PVDF membrane. Recombinant scFv was detected with an anti-c-Myc mAb (WB). Molecular mass is given in kDa on the left-hand side. (B) A300E mAb, scFv and BiTE recognize endogenous ADAM17 on HEK-293 cells. Untransfected HEK-293 cells were treated with A300E mAb, scFv or BiTE. For detection of scFv and BiTE, an anti-c-Myc mAb was used (grey peaks) followed by an APC-labelled donkey anti-mouse IgG. The samples were analysed with a FACScan flow cytometer. Negative controls were stained with anti-c-Myc mAb alone (white peaks). (C) A300E mAb, scFv and BiTE recognize truncated ADAM17 on HEK-293 cells expressing the cysteine-rich domain of human ADAM17 comprising the disintegrin-like domain and the membrane-proximal cysteine-rich extension followed by the transmembrane region of human ADAM17 (ADAM17_DE). HEK-293 cells were treated with A300E mAb, scFv or BiTE. For detection of scFv and BiTE, an anti-c-Myc mAb was used (grey peaks for HEK-293 untransfected and black peaks for HEK-293-ADAM17_DE) followed by an APC-labelled donkey anti-mouse IgG. The samples were analysed with a FACScan flow cytometer.
